Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
VIVES Partners is a venture capital fund established in 2004 by UCLouvain, located in Belgium. The firm manages multiple funds, including VIVES I, VIVES II, and VIVES Inter University Fund, focusing on early-stage and growth-stage investments. VIVES has a portfolio of six companies and targets investments ranging from €100,000 to €7 million.
VIVES invests in high-tech companies primarily in life sciences, AgTech, and hard engineering. The fund targets early-stage to round A companies based in Europe, especially in countries neighboring Belgium. Investments emphasize strong intellectual property and significant market potential.
Notable portfolio companies include IntoPIX, specializing in video processing and image compression; ATB Therapeutics, which develops next-generation antibody-drug conjugates for cancer therapies; Nuclidium, focused on radiopharmaceuticals for cancer treatment; Eligo Biosciences, innovating in in vivo gene editing; Novadip Biosciences, working on regenerative medicine; and Cissoid, providing high-temperature semiconductor solutions.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.